Our return to office in 2022 coincided with a year of intense activity in our dispute resolution engagements and other areas of the practice. Wins at trial included a successful defense of Bard against antitrust tying allegations and successful support of J&J’s restructuring efforts as it addressed talc product liability cases (later addressed on appeal). Arbitration work included assessments of global collaboration and distribution agreements, analyses of commercially reasonable efforts, and quantum associated with licensing agreements. We also helped our clients secure significant settlements, including our assistance with ViiV’s patent litigation involving HIV products that resulted in a $1.25 billion settlement.
2022 was a year of growth for other areas of the Life Sciences practice, as well. Our Strategy consulting efforts notably included some new work on the global commercialization challenges for cell and gene therapies and new work on pricing and access for high-cost, rare disease therapies. Our Policy consulting work included a focus on health equity and the life sciences implications of the US Inflation Reduction Act. See our high-level summary of some of the IRA implications in this recent three-part series.
Finally, I am happy to report that our practice itself grew as well in 2022! bioStrategies Group, a Chicago-based consultancy focused on life sciences strategy consulting, joined us late in the year, providing 17 new colleagues and broadening our geographic scope and subject-matter depth. Our Payor and Economic Research speaker series continue to broaden our network of friends and experts and invigorate our efforts to bring innovative ideas to our clients.
We are happy to share this update, which describes representative engagements from this past year and summarizes our ideas and activities.
